For research use only. Not for therapeutic Use.
Farletuzumab ecteribulin（Cat No.:I042108）is a combination therapy being investigated for the treatment of certain cancers, particularly ovarian cancer. Farletuzumab is a monoclonal antibody that targets the folate receptor alpha (FRα), which is overexpressed in some cancer cells. Ecteribulin is a synthetic drug that inhibits microtubule dynamics, leading to cancer cell death. The combination of farletuzumab and ecteribulin aims to improve the efficacy of treatment by both targeting cancer cells and disrupting their ability to divide and proliferate. It is being studied in clinical trials to assess its safety and potential to enhance cancer treatment outcomes.
| Catalog Number | I042108 |
| CAS Number | 2407465-18-1 |
| Purity | ≥95% |
